Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment.
Lechner L, Opitz R, Silver MJ, Krabusch PM, Prentice AM, Field MS, Stachelscheid H, Leitão E, Schröder C, Fernandez Vallone V, Horsthemke B, Jöckel KH, Schmidt B, Nöthen MM, Hoffmann P, Herms S, Kleyn PW, Megges M, Blume-Peytavi U, Weiss K, Mai K, Blankenstein O, Obermayer B, Wiegand S, Kühnen P. Lechner L, et al. Among authors: weiss k. Sci Transl Med. 2023 Jul 19;15(705):eadg1659. doi: 10.1126/scitranslmed.adg1659. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467315
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Clément K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C, Puder L, Fiedorek F, Gottesdiener K, Kleinau G, Heyder N, Scheerer P, Blume-Peytavi U, Jahnke I, Sharma S, Mokrosinski J, Wiegand S, Müller A, Weiß K, Mai K, Spranger J, Grüters A, Blankenstein O, Krude H, Kühnen P. Clément K, et al. Among authors: weiss k. Nat Med. 2018 May;24(5):551-555. doi: 10.1038/s41591-018-0015-9. Epub 2018 May 7. Nat Med. 2018. PMID: 29736023 Clinical Trial.
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Clément K, et al. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
Personality of marathon runners: a narrative review of recent findings.
Braschler L, Thuany M, de Lira CAB, Scheer V, Nikolaidis PT, Weiss K, Knechtle B. Braschler L, et al. Among authors: weiss k. EXCLI J. 2024 Mar 27;23:441-474. doi: 10.17179/excli2024-6907. eCollection 2024. EXCLI J. 2024. PMID: 38741728 Free PMC article. Review.
Repeat it without me: Crowdsourcing the T1 mapping common ground via the ISMRM reproducibility challenge.
Boudreau M, Karakuzu A, Cohen-Adad J, Bozkurt E, Carr M, Castellaro M, Concha L, Doneva M, Dual SA, Ensworth A, Foias A, Fortier V, Gabr RE, Gilbert G, Glide-Hurst CK, Grech-Sollars M, Hu S, Jalnefjord O, Jovicich J, Keskin K, Koken P, Kolokotronis A, Kukran S, Lee NG, Levesque IR, Li B, Ma D, Mädler B, Maforo NG, Near J, Pasaye E, Ramirez-Manzanares A, Statton B, Stehning C, Tambalo S, Tian Y, Wang C, Weiss K, Zakariaei N, Zhang S, Zhao Z, Stikov N; ISMRM Reproducible Research Study Group and the ISMRM Quantitative MR Study Group. Boudreau M, et al. Among authors: weiss k. Magn Reson Med. 2024 May 10. doi: 10.1002/mrm.30111. Online ahead of print. Magn Reson Med. 2024. PMID: 38730562
Ultra-Cycling- Past, Present, Future: A Narrative Review.
Tiemeier L, Nikolaidis PT, Chlíbková D, Wilhelm M, Thuany M, Weiss K, Knechtle B. Tiemeier L, et al. Among authors: weiss k. Sports Med Open. 2024 Apr 29;10(1):48. doi: 10.1186/s40798-024-00715-7. Sports Med Open. 2024. PMID: 38679655 Free PMC article. Review.
2,149 results